{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihhzmxc36ji6fhqfnre7u7dei2aw5rtcfkochn4i4hsjqlqanc5l4",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3merb3esdsiz2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigsgkzjptwmyqdsnagyuhh5yvkt2gol4eyuesajhf2ilhsbudg5jy"
    },
    "mimeType": "image/jpeg",
    "size": 750069
  },
  "path": "/news/2026-02-class-drug-aggressive-leukemia.html",
  "publishedAt": "2026-02-13T14:06:35.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Oncology & Cancer"
  ],
  "textContent": "Hyperactive signaling pathways of some aggressive blood cancer cells can be tamped down by a previously unrecognized protein complex, ensuring the cancer's survival. If one component of the complex is deleted or removed, the cancer cells are sent into overdrive and die, finds a Yale-led study published in Science Signaling.",
  "title": "Study identifies a new class of drug targets for aggressive leukemia"
}